Bisphosphonate Therapy for Osteogenesis Imperfecta
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00159419 |
Recruitment Status :
Completed
First Posted : September 12, 2005
Results First Posted : March 31, 2016
Last Update Posted : June 14, 2017
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Osteogenesis Imperfecta Osteoporosis Paget Disease of Bone | Drug: Alendronate Drug: Pamidronate | Phase 4 |
The study is designed to evaluate the efficacy and safety of "Bisphosphonate Therapy for Osteogenesis Imperfecta (OI)." OI is an inherited disorder of collagen synthesis. Collagen is the major structural protein of the matrix of tendons, skin, and bones. Affected persons have low bone mineral density (and experience multiple fractures and progressive bony deformity). In its most severe form, the disorder is lethal in infancy. We plan to characterize the changes effected by oral bisphosphonate therapy and compare them to a regimen of intravenous bisphosphonate therapy in a group of children with OI.
Additionally, we have begun to treat patients with OI and other conditions of low bone mineralization for age who are not eligible for the standard protocol (too young, history of abdominal pain, etc.) with bisphosphonate. We also plan to screen the parents and siblings of our patients diagnosed with osteogenesis imperfecta, in order to determine if they also have osteoporosis.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 18 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Bisphosphonate Therapy for Osteogenesis Imperfecta |
Study Start Date : | August 1999 |
Actual Primary Completion Date : | August 2008 |
Actual Study Completion Date : | August 2008 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Alendronate
1 mg/kg po qd rounded to nearest 10 or 20 mg dose
|
Drug: Alendronate
Other Name: fosamax |
Active Comparator: Pamidronate
3 mg/kg IV q4 months
|
Drug: Pamidronate |
- Bone Mineral Density [ Time Frame: 2 years ]By Dual-energy x-ray absorptiometry. Results were reported as z-scores as well as as absolute values. The Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean with negative numbers indicating values lower than the mean and positive values higher. Higher Z scores indicate a better outcome", or similar, as accurate and appropriate.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 3 Years to 21 Years (Child, Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
-
Diagnosis of OI, as defined by genetic analysis revealing a defect of type I collagen, OR by bone mineral density (BMD) <2.5 standard deviations (SD) for age plus two of the following:
- Family history of OI
- Frequent fractures
- Blue sclerae
- Multiple wormian bones on skull x-ray
- Hearing disturbance
- Dentinogenesis imperfecta
- Age between 3 and 21 years at the start of the study period.
- Children must be able to swallow whole tablets
- Parents of children must be able to understand protocol and give informed consent.
Exclusion Criteria:
- Therapy with bisphosphonates during the past 12 months.
- Other "non-traditional" therapy for OI in the last 6 months, such as growth hormone or anabolic steroids.
- Other chronic diseases besides OI that interfere with bone morphology or gastrointestinal absorption

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00159419
Principal Investigator: | Linda A DiMeglio, MD, MPH | Indiana University School of Medicine |
Responsible Party: | Linda DiMeglio, MD, MD, Indiana University |
ClinicalTrials.gov Identifier: | NCT00159419 |
Other Study ID Numbers: |
9902-30 |
First Posted: | September 12, 2005 Key Record Dates |
Results First Posted: | March 31, 2016 |
Last Update Posted: | June 14, 2017 |
Last Verified: | May 2017 |
Osteogenesis Imperfecta Fractures Pediatric Osteoporosis Juvenile Pagets |
Osteoporosis Osteogenesis Imperfecta Bone Diseases Osteitis Deformans Bone Diseases, Metabolic Musculoskeletal Diseases Metabolic Diseases Osteochondrodysplasias |
Bone Diseases, Developmental Genetic Diseases, Inborn Collagen Diseases Connective Tissue Diseases Alendronate Pamidronate Bone Density Conservation Agents Physiological Effects of Drugs |